```html

Quasi‑myocardial Infarction (Stress‑Induced Cardiomyopathy)

Overview

Stress‑induced cardiomyopathy, also known as Takotsubo cardiomyopathy or “broken‑heart syndrome,” is a temporary weakening of the heart muscle that mimics a heart attack (myocardial infarction) but occurs without the typical blockage of a coronary artery. The condition was first described in Japan in 1990, where the left ventricle takes on a shape resembling a Japanese octopus‑trap (takotsubo) on imaging studies.

Who it affects: The classic demographic is post‑menopausal women, who account for roughly 80–90 % of reported cases. However, men, younger adults, and children can also be affected, especially after intense emotional or physical stress.

Prevalence: In the United States, an estimated 1–2 % of patients who present with symptoms of an acute coronary syndrome are ultimately diagnosed with Takotsubo cardiomyopathy.<sup>1</sup> Annual incidence appears to be rising, likely due to greater awareness and use of cardiac imaging; recent registry data suggest 5–10 cases per 100,000 hospital admissions.<sup>2</sup>

Symptoms

Symptoms are often indistinguishable from a classic heart attack and may develop suddenly or over several hours.

• Chest pain or pressure – usually central, may radiate to the left arm, jaw, or back.
• Shortness of breath – can be at rest or with exertion.
• Palpitations – awareness of a rapid or irregular heartbeat.
• Dizziness or light‑headedness – especially if blood pressure drops.
• Syncope (fainting) – rare but possible.
• Nausea, vomiting, or abdominal discomfort – often accompanying chest symptoms.
• Extreme fatigue – may persist for weeks after the acute episode.
• Emotional triggers – intense grief, fear, anger, or surprise immediately before onset.
• Physical triggers – major surgery, acute asthma attack, severe infection, or neurologic events such as stroke.

Causes and Risk Factors

Pathophysiology

Although the exact mechanism remains under investigation, several inter‑related processes are thought to contribute:

1. Catecholamine surge – a sudden release of stress hormones (epinephrine, norepinephrine) can cause direct toxicity to heart muscle cells and coronary artery spasm.
2. Microvascular dysfunction – impaired blood flow in the tiny vessels of the heart, despite open major coronary arteries.
3. Coronary artery spasm – transient narrowing that reduces oxygen delivery.
4. Metabolic and inflammatory changes – stress can trigger cytokine release, damaging myocardial tissue.

Risk Factors

• Female sex, especially post‑menopausal (average age 67 y).
• History of anxiety, depression, or other psychiatric disorders.
• Recent emotional shock (e.g., death of a loved one, financial loss).
• Acute physical stressors (surgery, severe illness, trauma).
• Use of certain drugs that increase catecholamines (e.g., cocaine, sympathomimetics).
• Pre‑existing cardiovascular disease (though many patients have normal coronary arteries).

Diagnosis

Because the presentation mimics an acute myocardial infarction, the diagnostic work‑up follows a similar urgent pathway.

Initial Evaluation

• Electrocardiogram (ECG) – often shows ST‑segment elevation or depression, T‑wave inversion, and sometimes QT‑interval prolongation.
• Cardiac biomarkers (troponin, CK‑MB) – usually modestly elevated, lower than expected for the degree of ECG change.
• Chest X‑ray – may be normal or show pulmonary congestion.

Definitive Imaging

1. Echocardiography – first‑line imaging. Typical findings include:
   • Apical ballooning (classic “takotsubo” shape) with basal hyperkinesis.
   • Mid‑ventricular or basal variants in 20‑30 % of cases.
2. Coronary angiography – performed to rule out obstructive coronary artery disease. In Takotsubo, the coronary arteries are usually normal or have only mild disease.
3. Cardiac MRI – helps differentiate from myocarditis or infarction; shows myocardial edema without late gadolinium enhancement typical for infarction.

Diagnostic Criteria

The most widely used are the Mayo Clinic Criteria (must meet all):

1. Transient hypokinesis, akinesis, or dyskinesis of the LV mid‑segments with or without apical involvement.
2. Absence of obstructive coronary disease or evidence of acute plaque rupture.
3. New ECG abnormalities (ST‑segment elevation/depression, T‑wave inversion) or modest troponin rise.
4. Absence of pheochromocytoma or myocarditis.

Treatment Options

Management focuses on supportive care, preventing complications, and addressing the underlying stress response.

Acute Phase (first 48–72 hours)

• Oxygen – as needed to maintain SpO₂ > 94 %.
• Antiplatelet therapy – aspirin 81–325 mg daily is often given until coronary disease is excluded.
• Beta‑blockers – propranolol or metoprolol to blunt catecholamine effects (unless contraindicated).
• ACE inhibitors/ARBs – to reduce afterload and support LV recovery; commonly started once the patient is hemodynamically stable.
• Diuretics – for pulmonary congestion or significant fluid overload.
• Anticoagulation – if left‑ventricular thrombus is seen on echo (usually low‑molecular‑weight heparin → warfarin or DOAC for 3–6 months).

Recovery Phase (weeks to months)

• Continue beta‑blocker and ACE‑I/ARB for at least 3–6 months; many patients wean off once LV function normalizes.
• Cardiac rehabilitation programs improve functional capacity and teach stress‑management techniques.
• Psychological support (counselling, CBT, mindfulness) is essential, especially for patients with obvious emotional triggers.

Procedural Interventions

Procedures are rarely needed but may be required if complications arise:

• Intra‑aortic balloon pump (IABP) or impella for cardiogenic shock.
• Ventricular assist device (VAD) in refractory cases.

Living with Quasi‑myocardial Infarction (Stress‑Induced Cardiomyopathy)

Daily Management Tips

• Medication adherence – take prescribed drugs exactly as directed; missing doses can precipitate relapse.
• Monitor symptoms – keep a diary of chest discomfort, shortness of breath, or palpitations. Report any worsening promptly.
• Regular follow‑up imaging – repeat echo at 4–6 weeks and again at 3 months to document recovery.
• Stress‑reduction strategies – practice deep‑breathing, progressive muscle relaxation, yoga, or tai chi daily.
• Physical activity – start with light walking, advancing to moderate aerobic exercise (150 min/week) as tolerated and cleared by your cardiologist.
• Sleep hygiene – aim for 7–9 hours of quality sleep; poor sleep increases catecholamine levels.
• Limit stimulants – avoid excess caffeine, nicotine, and illicit stimulants (e.g., cocaine).
• Vaccinations – keep flu and COVID‑19 vaccines up‑to‑date to prevent infections that could trigger a relapse.

Prevention

Because the trigger is often abrupt, prevention revolves around reducing baseline stress and managing underlying conditions.

• Psychological health – treat anxiety or depression with therapy, medications, or both.
• Stress‑management programs – mindfulness‑based stress reduction (MBSR) has shown benefit in reducing catecholamine spikes.<sup>3</sup>
• Control cardiovascular risk factors – blood pressure, cholesterol, diabetes, and obesity.
• Avoid known drug precipitants – limit over‑the‑counter decongestants, ephedra, and high‑dose hormonal therapies.
• Gradual exposure to physical stress – for athletes or patients undergoing surgery, pre‑operative conditioning can blunt the hormonal surge.

Complications

Although most patients recover fully within 4–8 weeks, serious complications can occur, particularly in the acute phase.

• Heart failure – reduced ejection fraction can lead to pulmonary edema.
• Cardiogenic shock – occurs in ~5 % of cases; requires intensive‑care support.
• Life‑threatening arrhythmias – ventricular tachycardia/fibrillation or severe bradyarrhythmias.
• Left‑ventricular thrombus – reported in 2–5 % of patients; can cause stroke or peripheral emboli.
• Stroke – embolic events from LV thrombus or atrial fibrillation.
• Recurrence – 5–10 % experience a repeat episode within 5 years; risk is higher in those with persistent emotional stressors.

When to Seek Emergency Care

References

1. Mayo Clinic. Takotsubo cardiomyopathy (broken‑heart syndrome). https://www.mayoclinic.org. Accessed May 2026.
2. Abraham, C. et al. “Epidemiology of Takotsubo syndrome: a systematic review.” J Am Heart Assoc. 2022;11:e025345.
3. Cleveland Clinic. “Takotsubo Cardiomyopathy.” https://my.clevelandclinic.org. Accessed May 2026.
4. American Heart Association. “Stress cardiomyopathy (Takotsubo)”. https://www.heart.org. 2024.
5. World Health Organization. “Cardiovascular diseases (CVDs) fact sheet”. 2023.

```